Landos Biopharma Gross Profit

Landos Biopharma (LABP) currently reports a gross profit of $0 as of March 2024. That compares with $-220K in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore Landos Biopharma's gross profit history and peer comparisons.

Landos Biopharma's gross profit increased from $-220K to $0 — a 100.0% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Landos Biopharma's gross profit of $0 is lower than the Healthcare sector average of $66B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Landos Biopharma reported $0 in gross profit as of March 2024. That compares with $-220K in the prior-year period — up 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for Landos Biopharma, and consider following LABP for alerts when major investors trade the stock.